Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
To clarify the mechanism underlying resistance to interferon (IFN) by the hepatitis C virus (HCV) in patients with chronic hepatitis, we attempted to develop an IFN-resistant HCV replicon from the IFN-sensitive 50-1 replicon established previously. By treating 50-1 replicon cells with a prolonged low-dose treatment of IFN-alpha and then transfecting the total RNA derived from the IFN-alpha-treated replicon cells, we successfully obtained four clones (named 1, 3, 4, and 5) of HCV replicon cells that survived against IFN-alpha (200 IU/ml). These cloned cells were further treated with IFN-alpha or IFN-beta (increased gradually to 2000 or 1000 IU/ml, respectively). This led to four replicon cell lines (alphaR series) possessing the IFN-alpha-resistant phenotype and four replicon cell lines (betaR series) possessing the IFN-beta-resistant phenotype. Furthermore, we obtained an additional replicon cell line (alphaRmix) possessing the IFN-alpha-resistant phenotype by two rounds of prolonged treatment with IFN-alpha and RNA transfection as mentioned above. Characterization of these obtained HCV replicon cell lines revealed that the betaR series were highly resistant to both IFN-alpha and IFN-beta, although the alphaR series containing alphaRmix were only partially resistant to both IFN-alpha and IFN-beta. Genetic analysis of these HCV replicons found one common amino acid substitution in the NS4B and several additional amino acid substitutions in the NS5A of the betaR series, suggesting that these genetic alterations are involved in the IFN resistance of these HCV replicons. These newly established HCV replicon cell lines possessing IFN-resistant phenotypes are the first useful tools for understanding the mechanisms by which HCV acquires IFN resistance in vivo.
Namba
Katsuyuki
K
Department of Molecular Biology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
Naka
Kazuhito
K
Dansako
Hiromichi
H
Nozaki
Akito
A
Ikeda
Masanori
M
Shiratori
Yasushi
Y
Shimotohno
Kunitada
K
Kato
Nobuyuki
N
D000998:Antiviral Agents / Q000494:pharmacology; D015152:Blotting, Northern; D015153:Blotting, Western; D002460:Cell Line; D003001:Cloning, Molecular; D016572:Cyclosporine / Q000494:pharmacology; D017930:Genes, Reporter; D016174:Hepacivirus / Q000502:physiology*; D006801:Humans; D016898:Interferon-alpha / Q000378:metabolism; D016899:Interferon-beta / Q000378:metabolism; D007372:Interferons / Q000378:metabolism*; D008156:Luciferases / Q000378:metabolism; D008954:Models, Biological; D010641:Phenotype; D010766:Phosphorylation; D012313:RNA / Q000737:chemistry / Q000378:metabolism; D012367:RNA, Viral / Q000737:chemistry; D012093:Replicon; D015398:Signal Transduction; D014162:Transfection; D017361:Viral Nonstructural Proteins / Q000737:chemistry; D014779:Virus Replication
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D017361:Viral Nonstructural Proteins; D012313:RNA; D016899:Interferon-beta; D016572:Cyclosporine; D007372:Interferons; D008156:Luciferases